OR WAIT null SECS
Tufts analysis uncovers various benefits to conducting decentralized clinical trials—including financial benefits
Medable Inc., a cloud platform company for patient-centered drug development, announced results from a Tufts Center for the Study of Drug Development (CSDD) analysis, which concluded that, on average, decentralized clinical trials (DCTs) are associated with reduced clinical trial timelines, and can offer net financial benefits ranging from five to 14 times for Phase II and Phase III trials, respectively. The findings are based off of financial modeling and trial data analysis from the Tufts CSDD and Tufts University School of Medicine, along with more than 150 clinical trials enabled by Medable software.
The analysis features several findings, including:
“Our investigation found that, on average, the financial returns to drug sponsors from shorter development times, lower clinical trial screen failure rates and fewer clinical trial protocol amendments associated with DCTs substantially exceeded the costs of investing in DCT technologies,” explains Joseph DiMasi, director of economic analysis at Tufts CSDD.